Mr. James Parsons reports
TRILLIUM THERAPEUTICS RECEIVES NOTICES OF ALLOWANCE FROM U.S. PATENT AND TRADEMARK OFFICE
Trillium Therapeutics Inc. has received notices of allowance from the U.S. Patent and Trademark Office for two patent applications covering the use of SIRPaFc for the treatment of cancer, U.S. patent application No. 13/320,629 and U.S. patent application No. 15/962,540. Trillium has two SIRPaFc biologics, TTI-621 and TTI-622, in clinical development. Both therapeutics target CD47, a do-not-eat-me signal that cancer cells use to evade immune destruction.
The 629 method of use application provides coverage for the use of SIRPaFc biologics to treat all CD47 plus cancer cells and tumours, including hematologic and solid cancers. Counterparts of this application have already been granted in Japan, Canada and Australia.
The 540 application has claims that cover TTI-622 composition of matter comprising human SIRPa linked to an IgG4 Fc region, as well as claims covering pharmaceutical compositions that contain TTI-622. A composition-of-matter patent for TTI-621 (SIRPa linked to an IgG1 Fc) has already been granted in the United States
(US 9,969,789) and other countries.
"Intellectual property remains a top priority for Trillium, and the allowance of these two important patents further strengthens our position in the SIRPaFc CD47 space," said Jan Skvarka, president and chief executive officer of Trillium. "In addition to our specific composition-of-matter claims covering both of our CD47-targeting agents, we have expanded our coverage to embrace the use of the SIRPaFc class of biologics to treat cancer. We are particularly pleased that the method of use patent also covers treatment of solid tumours."
About Trillium Therapeutics Inc.
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a do-not-eat-me signal that cancer cells frequently use to evade the immune system.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.